Psoriatic arthritis - golimumab (TA220)
Fast, easy summary view of NICE guidance on 'psoriasis'
NICE recommends golimumab as a possible treatment for people with psoriatic arthritis in the same circumstances as other drugs for this condition (see 'Who can have golimumab?*' below).
Who can have golimumab?*
You should be able to have golimumab if you have three tender and three swollen joints and you have already tried at least two disease-modifying drugs (DMARDs), given on their own or together, but they haven't worked.
Only people whose psoriatic arthritis improves enough by 12 weeks should be able to carry on with treatment.
When assessing whether your psoriatic arthritis has improved, healthcare professionals should take into account any disabilities or difficulties in communicating you may have.
*The circumstances described in this section are the same circumstances in which NICE recommends etanercept, infliximab and adalimumab (see www.nice.org.uk/guidance/TA199).
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: psoriasis
This page was last updated: 17 June 2013
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA220 Golimumab ar gyfer arthritis soriatig: deall canllawiau NICE (fformat MS Word)
Information for the public
The following implementation tools will be available shortly:
Psoriatic arthritis - golimumab: audit support
Implementation tools and resources
- Clinical audit tool
- Costing statement
- Biologic drugs for the treatment of inflammatory disease in rheumatology, dermatology and gastroenterology: commissioning guide
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.